Compounds > riluzole
Page last updated: 2024-11-03

riluzole and ER-Negative PR-Negative HER2-Negative Breast Cancer

riluzole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Speyer, CL2
Bukhsh, MA2
Jafry, WS2
Sexton, RE1
Bandyopadhyay, S1
Gorski, DH2
Nassar, MA1
Hachem, AH1
Khansa, RM1

Other Studies

2 other studies available for riluzole and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Breast cancer research and treatment, 2017, Volume: 166, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferatio

2017
Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
    Breast cancer research and treatment, 2016, Volume: 157, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug S

2016